Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial

BACKGROUND: Angiogenesis and activation of the epidermal growth factor (EGFR) pathway play an essential role in tumor proliferation and metastasis. Targeting angiogenesis or EGFR alone does not yield adequate tumor control in most solid tumors. Overcoming intrinsic and/or acquired resistance may nee...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Exp Hematol Oncol
मुख्य लेखकों: Subbiah, Vivek, Dumbrava, Ecaterina Ileana, Jiang, Yunfang, Thein, Kyaw Z., Naing, Aung, Hong, David S., Fu, Siqing, Piha-Paul, Sarina A., Tsimberidou, Apostolia M., Janku, Filip, Meric-Bernstam, Funda, Kurzrock, Razelle, Falchook, Gerald
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: BioMed Central 2020
विषय:
Research
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7171918/
https://ncbi.nlm.nih.gov/pubmed/32337094
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40164-020-00159-1
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन